BioNexus Gene Lab Corp.: 10-K filed 2024-04-16

Name: BioNexus Gene Lab Corp.: 10-K filed 2024-04-16
Creator: BioNexus Gene Lab Corp.

What BioNexus Gene Lab Corp. reported in its annual report filed 2024-04-16 (fiscal FY 2023): 34 published measures, 72 facts as tagged in accession 0001477932-24-002151.

This filing

Form: 10-K (annual report)
Filed: 2024-04-16
Fiscal period: fiscal FY 2023
Accession: 0001477932-24-002151 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BioNexus Gene Lab Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-12-31	11,399,793	USD
At 2022-12-31	8,740,162	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-12-31	1,741,941	USD
At 2022-12-31	2,075,149	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-12-31	9,657,852	USD
At 2022-12-31	6,665,013	USD
At 2021-12-31	7,179,779	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,629,043	USD	365
2022-01-01 to 2022-12-31	-355,966	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-1,301,595	USD	365
2022-01-01 to 2022-12-31	551,822	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	18	USD	365
2022-01-01 to 2022-12-31	0	USD	365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	9,770,806	USD	365
2022-01-01 to 2022-12-31	10,928,707	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	5,754,322	USD	365
2022-01-01 to 2022-12-31	108,168	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-382,576	USD	365
2022-01-01 to 2022-12-31	-450,498	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-12-31	-1,844,278	USD
At 2022-12-31	1,156,392	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-21,526	USD	365
2022-01-01 to 2022-12-31	-52,310	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-12-31	1,511,618	USD
At 2022-12-31	1,511,708	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,593,588	USD	365
2022-01-01 to 2022-12-31	-291,177	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-12-31	8,046,800	USD
At 2022-12-31	6,021,826	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	13,929	USD	365
2022-01-01 to 2022-12-31	12,479	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-12-31	1,630,923	USD
At 2022-12-31	2,004,077	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-12-31	1,402,180	USD
At 2022-12-31	1,861,015	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2023-12-31	1,137,770	USD
At 2022-12-31	977,807	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	1,329,498	USD	365
2022-01-01 to 2022-12-31	1,259,029	USD	365

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	8,441,308	USD	365
2022-01-01 to 2022-12-31	9,669,678	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-12-31	17,667,663	shares
At 2022-12-31	14,476,513	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-12-31	5,929,336	USD
At 2022-12-31	2,118,864	USD
At 2021-12-31	2,123,919	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-12-31	-5,011,891	USD
At 2022-12-31	-5,011,891	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-12-31	-677,294	USD
At 2022-12-31	-409,062	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit
At 2023-12-31	141,544	USD
At 2023-09-30	141,544	USD
At 2022-12-31	55,730	USD
At 2021-12-31	41,090	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2023-12-31	659,115	USD
At 2022-12-31	616,913	USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

Period	Value	Unit	Days
At 2023-12-31	12,255	USD
At 2022-12-31	30,866	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,607,517	USD	365
2022-01-01 to 2022-12-31	-303,656	USD	365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,629,043	USD	365
2022-01-01 to 2022-12-31	-355,966	USD	365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,897,275	USD	365
2022-01-01 to 2022-12-31	-664,766	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	4,409,122	USD	365
2022-01-01 to 2022-12-31	1,729,489	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	83,253	USD	365
2022-01-01 to 2022-12-31	91,427	USD	365

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-66,973	USD	365
2022-01-01 to 2022-12-31	-170,447	USD	365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-160,387	USD	365
2022-01-01 to 2022-12-31	544,108	USD	365

Inspect the source

Entity: BioNexus Gene Lab Corp. / CIK 0001737523
Captured: 2026-09-21T17:25:37.348Z
SEC response SHA-256: eebcf668b9e42f0c31bf1fe5b3c17450d7f4d836f715c9cebcc6a4fafbcff983

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001737523.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))